Setmelanotide Acetate
FDA-approved product (solution, subcutaneous), marketed as Imcivree.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Centrally acting antiobesity products
- FDA pharmacologic class
- Melanocortin 4 Receptor Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Setmelanotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm52.3% AI-predicted activityagainst E. coli50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- FinerenoneExisting use: Cardiovascular disease, Chronic kidney disease, Type 2 diabetes mellitus52.2% AI-predicted activityagainst E. coli50+ registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma52.0% AI-predicted activityagainst E. coli50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more52.0% AI-predicted activityagainst E. coli22 registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis51.9% AI-predicted activityagainst E. coli50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia51.8% AI-predicted activityagainst E. coli4 registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.6% AI-predicted activityagainst E. coli50+ registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more51.4% AI-predicted activityagainst E. coli14 registered studies
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.